
Prolongation of the share buyback program

The Board of Directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today resolved to prolong the duration of the share buyback until 26 July 2022

With reference to the company announcement published on 22 Jun 2022 regarding share buyback, the Board of Directors in Initiator have today resolved to prolong the duration of the share buyback until 26 July 2022. Initially the buyback was scheduled to be completed at 14 July 2022 at the latest, but as Initiator have not yet acquired the required number of shares amounting to 24,000 an extension of the buyback is necessary. Initiator will publish an announcement, when the buyback of 24,000 shares have been finalized on or before 26 July 2022.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB, with email address certifiedadviser@redeye.se and phone number +46 8 121 576 90, is the company's Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

[Prolongation of the share buyback program](#)